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Abstract: The use of probiotic microorganisms in clinical practice has increased in recent years and a
significant number of pregnant women are regular consumers of these products. However, probiotics
might modulate the immune system, and whether or not this modulation is beneficial for perinatal
outcomes is unclear. We performed a systematic review and meta-analysis to evaluate the reporting
of perinatal outcomes in randomized controlled trials including women supplemented with probiotic
microorganisms during pregnancy. We also analyzed the effects that the administration of probiotic
microorganisms exerts on perinatal outcomes. In the review, 46 papers were included and 25 were
meta-analyzed. Reporting of perinatal outcomes was highly inconsistent across the studies. Only
birth weight, cesarean section, and weeks of gestation were reported in more than 50% of the studies.
Random effects meta-analysis results showed that the administration of probiotic microorganisms
during pregnancy did not have any a positive or negative impact on the perinatal outcomes evaluated.
Subgroup analysis results at the strain level were not significantly different from main analysis results.
The administration of probiotic microorganisms does not appear to influence perinatal outcomes.
Nonetheless, future probiotic studies conducted in pregnant women should report probiotic strains
and perinatal outcomes in order to shed light upon probiotics’ effects on pregnancy outcomes.
Keywords: probiotics; safety; pregnancy; perinatal outcomes; strains; meta-analysis; PRISMA
1. Introduction
According to the World Health Organization (WHO), Food and Agriculture Orga-
nization (FAO), and the International Scientific Association for Probiotics and Prebiotics
(ISAPP), probiotics are defined as “live microorganisms which when administered in ade-
quate amounts confer a health benefit on the host” [1,2]. Similarly, synbiotic products are
combinations of probiotic microorganisms and a beneficial substrate constituted by the
prebiotic [3]. The use of probiotic microorganisms is widespread, and probiotic/synbiotic
products are available in the global market labeled as food supplements or medical prod-
ucts depending on different regulations [4]. The market value of these products was
estimated to account for USD 54 billion in 2020 and this trend suggests that it will grow
substantially in the next years [5].
Probiotic microorganisms have been used for a plethora of clinical indications such
as lactose malabsorption, diarrhea, bowel syndrome, and infection, among others [6].
In pregnant women, the administration of these microorganisms has been proposed to
alleviate gastrointestinal symptoms, improve glycemic control, reduce oxidative stress,
and lower the incidence of asthma, atopic sensitization, and allergic disease in offspring,
among other outcomes [7–9]. However, clinical evidence remains far from conclusive [10].
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Pregnancy is a dynamic immunological process in which pro- and anti-inflammatory
status concur in order to facilitate the different stages of gestation [11]. Whereas a pro-
inflammatory stage is necessary for successful embryo implantation and placentation
during early pregnancy, an anti-inflammatory switch is required to allow fetal growth
during mid-pregnancy. Finally, once fetal development is complete, another physiological
pro-inflammatory status leads to labor and delivery [11]. Disruption of this immunological
process is linked to adverse perinatal outcomes such as miscarriage, intrauterine growth
restriction, and preterm birth [12].
Immune stimulation is among the different mechanisms of action attributed to pro-
biotic microorganisms [13]. One study observed that pregnant women supplemented
with a combination of Bifidobacterium longum, Lactobacillus delbrueckii, and Streptococcus
thermophilus from 32 weeks of gestation to delivery had higher concentrations of proin-
flammatory cytokines, namely interleukine-5 (IL-5), interleukine-6 (IL-6), tumor necrosis
factor- α (TNF- α), and granulocyte-macrophage colony-stimulating factor (GM-CSF) [14].
On the other hand, a recent study monitored populations of immune cells after the ad-
ministration of Lactobacillus reuteri to pregnant women during mid-gestation, observing
that the number of activated regulatory T cells was lower in the group supplemented
with Lactobacillus reuteri in comparison to the placebo [15]. Hence, the administration of
probiotic microorganisms can potentially stimulate or suppress inflammatory status and
immune response during gestation, but whether or not these changes are beneficial to
pregnancy is unclear [14,16].
Previous reviews have evaluated the effect that the administration of probiotic microor-
ganisms during pregnancy exerts on maternal and perinatal outcomes, concluding that pro-
biotic microorganisms do not increase or decrease the incidence of these outcomes [10,17,18].
These studies have only evaluated these microorganisms at the genus or species level.
However, mounting evidence suggests that probiotic effects are strain-dependent, and
strain-specificity is usually a poorly reported aspect of probiotics research [19]. Further-
more, studies explicitly designed to assess the safety of probiotic/synbiotic interventions
are lacking [20].
In the light of these studies and given the rapid growth of literature regarding pro-
biotic microorganisms, we aimed to evaluate the reporting of perinatal outcomes in ran-
domized controlled trials (RCT) studying the administration of probiotic microorganisms
during pregnancy and to explore the associations between the administration of probi-
otic microorganisms during pregnancy and perinatal outcomes considering the role that
strain-specificity could play in the associations.
2. Materials and Methods
We conducted a systematic review and meta-analysis of randomized controlled trials
studying the administration of probiotic microorganisms during pregnancy. The present
systematic review was conducted according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement (PRISMA) [21]. The protocol for this study was
registered in the PROSPERO database with the number “CRD42020216531.” The PRISMA
checklist is presented in Supplementary 5.
2.1. Literature Search
We carried out an automatized search in three databases, PubMed (MEDLINE), Scopus,
and Cochrane Controlled Register of Trials (CENTRAL), during August–October 2020.
The records dated from inception up to August 2020. The databases were searched by
one reviewer. The language was restricted to English, and only full articles published
in scientific journals were included in the research. A detailed search strategy based on
patients, interventions, comparators, outcomes, and study design (PICOS) chosen for the
present study is presented in Supplementary 1.
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2.2. Inclusion and Exclusion Criteria
We selected randomized controlled trials enrolling pregnant women in which at least
one group of study was treated with probiotic or synbiotic preparations, with specified
microorganisms and dosage, and at least one group of comparison received no treatment,
routine care, or placebo, independently of the blinding process.
We excluded grey literature such as conference abstracts, workshops, and government
reports, as well as other study designs. However, references from systematic reviews were
searched for additional articles. Trials studying fermented food or generic products (i.e.,
probiotic food or probiotic supplement) without specifying the dosage and microorganisms
provided were excluded. Studies comparing the use of probiotic preparations against
antibiotics, as well as studies without follow-up to delivery, were also excluded. Secondary
analyses of previous studies were not included in the review, but they were screened for
additional information when not reported in the main analysis and were thus cited in
tables when appropriate.
2.3. Study Outcomes
The prespecified main outcomes of the study consisted of the number of weeks of
gestation, birth weight, preterm birth, cesarean section, low birth weight, macrosomia,
small for gestational age (SGA), large for gestational age (LGA), miscarriage, and still-
birth. Secondary outcomes reported in the studies, namely cases of malformation, Apgar
test score, umbilical cord pH, anthropometric measures at birth, neonatal death, and ad-
mission to neonatal intensive care unit, were also discussed but were not considered for
meta-analysis.
Preterm birth was defined as a baby born alive before 37 completed weeks of gesta-
tion [22]. SGA was defined as a live birth with a weight below the 10th percentile for the
gestation age, while LGA was defined as a live birth with a weight above the 90th per-
centile [23]. According to ICD-10, low birth weight was considered as a live birth weighing
less than 2500 g at delivery [24], while macrosomia was defined as a live birth weighing
more than 4000 g at delivery in accordance with the American College of Obstetricians and
Gynecologists [25]. When authors provided different definitions for these outcomes, they
were specified in tables (Supplementary 3: Table S2).
2.4. Data Extraction
A template was created for data extraction, and two reviewers independently extracted
the data from the included studies. The template consisted of the following items: Authors,
year of acceptance for publication, country where the study was conducted, study design,
sample size at randomization, sample size of groups analyzed, specific previous conditions
(i.e., women with gestational diabetes mellitus), comparison group, main objective of the
study, probiotic microorganisms, dosage and posology, vehicle of administration, duration
of treatment, conflict of interest, and raw data or statistics on the reported perinatal
outcomes (i.e., mean and standard deviation).
Studies using probiotic/synbiotic products provided by a company without stating
the manufacturer’s contribution to the paper were considered to present potential conflicts
of interest. Disagreements between both reviewers were resolved by a third reviewer.
2.5. Quality Assessment
Two reviewers independently evaluated the quality of the included studies using
the Cochrane risk-of-bias tool for randomized trials (RoB 2.0) [26]. Five domains were
evaluated, including the randomization process, deviations from intended interventions,
missing outcome data, measurement of the outcome, and selection of reported results.
Follow-up losses >20% were considered as a high risk of bias when assessing missing
outcome data. Protocols of included studies were checked when assessing selective report
bias. Regarding the overall risk of bias, we applied the following scheme based on the
Cochrane Handbook recommendations [27]: One item rated as “high risk of bias” or three
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or more items rated as “some concerns” = high risk of bias; one or two items rated as “some
concerns” = some concerns; all items rated as “low risk of bias” = low risk of bias. Any
disagreement was discussed with a third reviewer.
2.6. Data Synthesis and Statistical Analysis
We conducted a random effects meta-analysis of the studies included in the review
based on criteria selected to avoid potential bias when pooling results. Selected inclusion
criteria for the meta-analysis were as follows: (1) Study population consisting of pregnant
women without specified previous pathologies, and (2) studies reporting raw data or
statistics on the specific perinatal outcome. We did not exclude women at high risk of
atopic sensitization from the meta-analysis.
Groups of study assessing additional interventions other than dietary advice (i.e.,
probiotics + vitamin D) were excluded from analyses. If one study reported two or more
groups treated with different probiotic microorganisms, they were combined. Data were
pooled as relative risk and 95% confidence interval (95% CI) or mean ± standard deviation
(SD), and the I2 statistic was used to assess heterogeneity across the studies. We used the
Mantel–Haenszel statistical method in all of the analyses. Data reported as mean ± 95% CI
were transformed into mean ± SD. These approaches are recommended by the Cochrane
handbook [27]. When data were reported as median and interquartile range or median
and range, they were transformed into mean ± SD using the method developed by Wan
et al. [28]. Additionally, we provided subgroup analyses excluding these estimated statistics
in order to assess how these approaches could influence pooled results (Supplementary 4).
Only outcomes reported in at least two trials that met the aforementioned inclusion
criteria were pooled. When preterm birth cases were considered as an exclusion criterium
in the papers, we added those preterm birth cases to the groups analyzed. There was
only one paper studying synbiotic products that met the inclusion criteria. Therefore, only
probiotic studies were finally meta-analyzed.
Subgroup analyses were conducted based on reported strains of microorganisms.
Accordingly, we pooled data on outcomes reported in at least two studies using the same
microorganism strain or the same combination of strains.
Finally, we created funnel plots for each main analysis including at least 10 studies.
Publication bias was assessed by visual inspection of the funnel plots.




A total of 26,579 records were screened after removing duplicates, leaving 115 articles
available for eligibility, including 10 references from other previous reviews. Of the eligible
articles, 87 met the inclusion criteria and were further evaluated to exclude any secondary
analysis of a previous research. Finally, 46 RCTs were included in the systematic review
and 25 RCTs were included in the meta-analysis. Secondary analyses of previous studies
were screened for additional data if they were not reported in the original research, and
thus were cited in tables when applicable. The article selection process is presented in
Figure 1 according to the PRISMA flow diagram of trials.
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow 
diagram of trials. 
3.2. Characteristics of the Studies 
Characteristics of studies included in the systematic review are presented in Table 1.
Figure 1. Preferred R porting Items for Sy tematic Reviews and Meta-Analysis (PRISMA) flow diagram of trials.
3.2. Characteristics of the Studies
Characteristics of studies included in the systematic review are presented in Table 1.
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In the present review, 46 randomized controlled trials were included. A total of
8519 pregnant women participated in these studies. Of the analyzed studies, 42 trials
evaluated the administration of probiotic preparations to pregnant women whereas 4
studies evaluated the administration of synbiotic products. The included papers dated
from 2001 to 2020. Of the studies, 15 were conducted in Iran [30,31,33–36,40,46–48,50,
51,64,70,72]; 4 trials were conducted in Finland [49,55,56,69]; 3 in New Zealand [66,73,
74]; 3 in Australia [37,38,67]; 2 each in Canada [71,75], Germany [43,54], Taiwan [45,
68], and Ireland [58,59], and the remaining 13 RCTs were conducted in other different
countries. Most of the studies recruited healthy pregnant women. However, 10 trials
included only pregnant women with gestational diabetes mellitus [35,36,40,46,48,50–52,59,
64], 4 studies included exclusively obese/overweight pregnant women [38,44,58,66], and 1
study included only pregnant women carrying group B streptococcus (GBS) [45].
Regarding the main objectives of the studies, the most common were improving
insulin/glucose metabolism (13 studies) [30,33,34,40,44,46,50,52,58,64,69,70,72]; preventing
eczema, allergic disease, or atopic sensitization (10 studies) [29,37,41,49,53–55,65,68,73];
improving oxidative stress status and inflammatory profile (8 studies) [14,36,46–48,51,64];
modifying the mother’s or infant’s microbiota (5 studies) [14,61,63,65,75]; and preventing
GBS occurrence (4 studies) [45,67,71,74]. Other outcomes included bacterial vaginosis,
mastitis, pregnancy outcomes, safety assessment, maternal anthropometric measures,
infant colic, genetic profile, and infant diarrhea or gut integrity.
In respect to the microorganisms administered, none of the included studies eval-
uated the administration of probiotic yeasts (i.e., Saccharomyces bourlardii) to pregnant
women. In the studies, 21 of the authors administered combinations of Bifidobacterium
and Lactobacillus species [30,32–36,38,41,44,47,48,50–53,56,60,66,67,69,73]; 18 authors stud-
ied the administration of Lactobacillus species only [29,31,37,42,43,45,49,54,58,59,63,64,67,
68,71,72,74,75]; 4 authors used combinations of Lactobacillus, Bifidobacterium, and Strep-
tococcus species [14,40,46,61]; 1 author evaluated Bifidobacterium species only [39]; and
the 2 remaining authors evaluated other combinations with different bacterial genera
(Propionibacterium and Lactococcus) [55,65]. Strains of microorganisms administered were
reported in 32 of the 46 included studies (70%). The reporting of strains was heterogeneous
across the studies, with authors reporting culture collection numbers (i.e., Lactobacillus
rhamnosus ATCC 53103), commercial designations (i.e., Bifidobacterium animalis HN019), or
references to the name of the person who originally isolated the strain (i.e., Lactobacillus
rhamnosus GG). The most frequently used strains, alone or in combination with other
strains, were L. rhamnosus GG (nine studies) [37,38,41,49,54–56,60,68], B.animalis BB-12
(seven studies) [33,34,38,40,41,56,66], L. rhamnosus GR-1 (six studies) [43,45,63,67,71,75],
L. reuteri RC-14 [43,45,63,67,71,75], L. acidophilus LA-5 (four studies) [33,34,40,41], and L.
rhamnosus HN001 (three studies) [69,73,74].
Probiotic/synbiotic administration was only compared to placebo in 37 trials (80%) [29–
32,36–47,49–55,58,59,63–66,68,70–75], while 5 studies (11%) used a group with no treatment
or routine care as a comparison [14,33–35,67], and the remaining 4 papers (9%) analyzed
other additional comparison groups (i.e., probiotic + vitamin D) [48,56,60,69]. Microor-
ganisms were administered orally in all of the included studies. Administration vehicles
consisted of capsules in most of the cases (35 studies, 76%), with 3 studies using probiotic
yoghurt (6.5%) [33,34,70]; 3 studies using probiotic powder [53,60,61]; and 1 study each
using probiotic oil (2.2%) [29], tablets [14], and milk [41]. The two remaining studies (4.3%)
did not specify the vehicle used to administer the microorganisms [67,72].
The dosages of individual microorganisms were diverse, ranging from 5 × 105 CFU [14]
to 5 × 1010 CFU [64]. However, in some cases, the posology was unclear [34,35]. In other
cases, the dosages were defined as CFU/g, but the authors did not declare the mass of the
product administered.
Mean treatment duration was approximately 9 weeks, ranging from 3 weeks of
duration [67] to 26 weeks [56]. Women were treated with probiotic/synbiotic preparations
during the third trimester of gestation in most of the trials (34 studies, 74%) [2–37,39–42,45,
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46,48,49,52–55,58–61,64,65,67,68,70–73], through second and third trimesters in 7 studies
(15%) [38,44,50,56,66,74,75], through first and second trimesters in 3 studies [43,47,69], and
independently of the trimester of gestation in 1 study [63]. One author did not specify the
period of treatment [51].
Quality assessment results showed that 18 studies (39%) had a low risk of bias (high
methodological quality) [29–31,34–38,43,44,52,55,56,58,59,66,69,73], 15 studies (33%) had
an unclear risk of bias due to concerns in one or two of the items assessed [41,47,49–
54,60,64,65,68,70,71,73,74], and the remaining 13 studies (28%) had a high risk of bias (low
methodological quality) [14,32,33,39,40,42,45,46,48,61,63,67,75]. Detailed results of the risk
of bias assessment are presented in Supplementary 2: Table S1. Regarding conflicts of
interest, 9 studies (20%) showed no conflict of interest (clearly declaring manufacturer
contribution to the manuscript) [38,41,44,58,59,61,66,69,74], 28 studies (60%) had a potential
conflict of interest (product supplied by a private laboratory and unclear manufacturer
contribution to the manuscript) [14,30,31,33–37,40,42,43,45–52,56,63,64,67,68,70–72,75], and
the other 9 studies had an existing conflict of interest (either declared conflict of interest or
clear existing relationship with the manufacturer) [29,32,39,53–55,60,65,73].
3.3. Reporting of Perinatal Outcomes
A summary of the studies included in the systematic review and in the meta-analysis
based on the reporting of perinatal outcomes is presented in Table 2. Detailed data on the
perinatal outcomes reported in the included studies are presented in Supplementary 3:
Table S2. Finally, cases of miscarriage and stillbirth were not meta-analyzed due to a lack
of consensus on the outcome definition across the studies.





Reviewed Studies n Intervention
Number of Pooled
Studies n Pooled RR/MD (95% CI) I
2
Preterm Birth
19 4903 Probiotic 11 2934 RR = 1.16(0.78–1.71) 16%
2 155 Synbiotic 0 - - -
Weeks of Gestation
23 4144 Probiotic 13 2074 MD = 0.03(−0.21–0.27) 78%
1 60 Synbiotic 0 - - -
Birth Weight
28 6666 Probiotic 13 3578 MD = −5.57(−38.48–27.34) 0%
1 60 Synbiotic 0 - - -
Low Birth Weight
1 433 Probiotic 0 - - -
0 - Synbiotic 0 - - -
Macrosomia
10 1654 Probiotic 3 94 RR = 0.84(0.30–2.34) 60%
1 60 Synbiotic 0 - - -
SGA
5 1301 Probiotic 0 - - -
0 - Synbiotic 0 - - -
LGA
7 1436 Probiotic 2 316 RR = 0.98(0.60–1.61) 0%
0 - Synbiotic 0 - - -
Cesarean Section
26 5952 Probiotic 17 3445 RR = 0.93(0.83–1.04) 0%
1 60 Synbiotic 0 - - -
Miscarriage or
Stillbirth
11 2595 Probiotic 0 - - -
0 - Synbiotic 0 - - -
LGA: Large for Gestational Age; MD: Mean Difference; RR: Relative Risk; SGA: Small for Gestational Age.
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As presented in Supplementary 3: Table S2, the reporting of perinatal outcomes
was completely heterogeneous across the studies. Only two authors described, in de-
tail, the perinatal outcomes in the cohort of study reporting data on all of the following
items: Cases of miscarriage/stillbirth, weeks of gestation, cases of preterm birth, birth
weight, cases of macrosomia or LGA, cases of low birth weight or SGA, and cesarean
section [38,69]. On the other hand, eight studies did not report data on any of the aforemen-
tioned items [30,33,35,40,42,47,67,72]. Regarding the main outcomes of the present review,
the most frequently reported outcome across the studies was birth weight (29 studies,
63%), followed by cesarean section (27 studies, 59%), weeks of gestation (24 studies, 52%),
preterm birth (<37 weeks of gestation, 21 studies, 46%), miscarriage/stillbirth (11 studies,
24%), macrosomia (10 studies, 22%), LGA (7 studies, 15%), SGA (5 studies, 11%), and
low birth weight (1 study, 2%). Other outcomes reported in the studies consisted of
neonatal hospitalization or admission to neonatal intensive care unit (NICU) (15 studies,
33%) [29,34,36–38,45,48,51,58,59,66,69–71,74], anthropometric measures at birth (i.e., head
circumference or birth length) (15 studies) [14,29,34,36,48–51,56,59,60,66,70,73,74], Apgar
test score at 1 or 5 minutes (11 studies, 24%) [14,45,48,51,56,59,60,69,71,74,75], malforma-
tion/fetal abnormalities (7 studies, 15%) [34,38,44,55,58,59,69], hypoglycemia (6 studies,
13%) [36,38,48,51,52,69], hyperbilirubinemia or jaundice (5 studies, 11%) [34,36,38,48,51],
induction of labor (3 studies, 7%) [44,59,75], polyhydramnios (3 studies) [36,48,51], cord
blood pH (2 studies, 4%) [69,75], preterm birth (<35 weeks of gestation, 2 studies) [46,64],
preterm birth (<34 weeks of gestation, 1 study, 2%) [38], and umbilical artery resistance
(1 study) [39].
3.4. Administration of Probiotics during Pregnancy and Length of Gestation
Eleven studies evaluated the administration of probiotic preparations to pregnant
women without previous pathologies reporting the cases of preterm delivery (<37 weeks
of gestation) in the groups analyzed. The random effects meta-analysis of these stud-
ies showed that probiotic administration during pregnancy did not have a statistically
significant impact on the odds of preterm birth in the groups of study (RR = 1.19, 95%
CI = 0.81–1.74). Heterogeneity across the studies was low (I2 = 14%; Figure 2). Visual
inspection of the funnel plot did not reveal potential publication bias (Figure 3).
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3.6. Administration of Probiotics during Pregnancy and Cesarean Section
Seventeen studies reported the cases of cesarean section in the groups of study and met
the inclusion criteria for the meta-analysis. The random effects meta-analysis of these stud-
ies showed that administration of probiotics during pregnancy did not influence cesarean
section rate (RR = 0.98, 95% CI = 0.87–1.10; Figure 10). The studies were homogeneous
(I2 = 0%). Visual inspection of the funnel plot did not reveal publication bias (Figure 11).
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Figure S9). In line with this, the subgroup analysis of two other authors that administered a
combination of L. rhamnosus GR-1 and L. reuteri RC-14 did not show a significant correlation
with cesarean section (RR = 0.85, 95% CI = 0.46–1.59, I2 = 0%; Supplementary 4: Figure S10).
4. Discussion
The present systematic review and meta-analysis aimed at evaluating the reporting of
perinatal outcomes in randomized controlled trials analyzing the effect that the administra-
tion of probiotic microorganisms might exert on these outcomes. We included 46 studies in
the present review, 25 of which were meta-analyzed. The random effects meta-analysis
results showed that the administration of probiotics during pregnancy was not associated
with any perinatal outcome evaluated. However, the reporting of perinatal outcomes was
completely heterogeneous across the included studies, and only birth weight, cases of
cesarean section, and weeks of gestation were reported in more than 50% of the studies.
By definition, probiotic microorganisms, when administered in adequate amounts,
confer a health benefit on the host [1,2]. Nonetheless, probiotics must also be safe for
their intended use [76]. In this sense, an exhaustive review on this subject including
384 RCTs involving probiotics, prebiotics, and synbiotics concluded that the reporting
of adverse events in most of these trials was lacking and inadequate [77]. Pregnant
women are an immunologically vulnerable population, and the mechanisms by which
probiotic microorganisms might stimulate or suppress the immune system are not clear [76].
Therefore, not only adverse events (which is out of the scope of the present review), but
also perinatal outcomes should be considered when conducting probiotic trials in pregnant
women.
Sample size is usually a limitation of probiotic trials when assessing differences in
perinatal outcomes [78,79]. In this regard, meta-analyses help to overcome this limitation
by pooling data from several studies. In line with the present research, other reviews and
meta-analyses on this topic have concluded that probiotics and synbiotics do not positively
or negatively influence perinatal outcomes [10,17,18]. Nonetheless, the authors of these
reviews coincide on affirming that the reporting of these outcomes is highly heterogeneous,
with some authors reporting only weeks of gestation at delivery [68] or cases of preterm
labor [64] without further considering other outcomes. Furthermore, some authors have
reported perinatal outcomes in secondary analyses even when they were not provided
in the original research [57,62]. This could imply selective report bias when assessing
probiotics safety.
The meta-analysis results showed that the administration of probiotics was not as-
sociated with preterm birth (RR = 1.19, 95% CI = 0.81–1.74) or birth weight (MD = −5.36,
95% CI = −37.60–26.89). The lack of association could be caused by the timing of the
intervention given that several included studies administered probiotic preparations from
the last 4–6 weeks of gestation to delivery or postpartum. However, the subgroup analysis
excluding these studies did not yield different results. Therefore, it seems unlikely that the
timing of the intervention would have a significant impact on meta-analysis conclusions.
Nonetheless, it is remarkable that only 142 cases of preterm birth were included in the
meta-analysis from a total of 2934 participants, which implies a low rate of preterm delivery
in these studies analyzed (4.8%) compared to global estimates (10.6%) [80]. Similar rates
of preterm birth were observed in another meta-analysis [10]. Given the low reported
incidence of preterm birth in the studies analyzed, future studies with a bigger sample size
are required to evaluate the effects of probiotics on this outcome.
Birth weight was mostly reported as a continuous variable in the studies. In this
sense, SGA and low birth weight were clearly underreported outcomes across the studies
and could not be included in the meta-analysis. On the other hand, the majority of the
studies reporting cases of LGA or macrosomia were conducted in pregnant women with
GDM and were thus excluded from the analyses. Finally, only three studies reporting
cases of macrosomia and two studies reporting LGA cases were meta-analyzed. Due to
the low number of pooled studies, it is not possible to draw solid conclusions from the
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meta-analyses regarding LGA and macrosomia. More studies are necessary to evaluate the
influence of probiotics administration on SGA and low birth weight.
Mounting evidence suggests that probiotics’ effects are strain-dependent [19]. How-
ever, the meta-analyses conducted to date were not able to pool data from specific strains
due to the heterogeneity of included studies. In the present review, we conducted subgroup
analyses of studies evaluating the administration of L. rhamnosus GG, L. rhamnosus GR-1,
and L. reuteri RC-14. In this regard, L. rhamnosus GR-1 has been suggested to present
beneficial properties for the prevention of preterm birth in animal models [81]. Our results
showed that the administration of L. rhamnosus GG was not associated with higher or lower
birth weight in the included studies. Similarly, neither L. rhamnosus GG nor L. rhamnosus
GR-1 in combination with L. reuteri RC-14, were associated with the number of weeks
of gestation of cesarean section rate. However, almost one-third of the authors did not
report the probiotic strains administered, and the small number of studies included in the
sub-analyses makes it impossible to draw strong conclusions from these results.
Finally, the present research is not exempt from limitations. We did not exclude studies
analyzing twin pregnancies, which could bias our results given that multiple pregnancies
have a higher risk of adverse perinatal outcomes. We did not ask the authors of the studies
for nonreported data, which could have increased the number of studies meta-analyzed.
Lastly, we did not analyze maternal outcomes (i.e., preeclampsia) or adverse events (i.e.,
diarrhea), which are subjects of much deeper research on probiotic safety.
5. Conclusions
The meta-analysis results at the genus or species level showed that the administration
of probiotic microorganisms during pregnancy does not have any positive or negative
impact on birth weight, length of gestation, and cesarean section. The sub-analyses at the
strain level did not modify these results. However, the number of studies reporting the
same perinatal outcome and evaluating the administration of the same probiotic strains
was very low, and it is thus not possible to draw strong conclusions from the sub-analyses
results regarding the effect that specific probiotic strains might exert on perinatal outcomes.
The reporting of perinatal outcomes was inconsistent across the included studies. Future
probiotic randomized controlled trials should report perinatal outcomes and probiotic
strains in order to shed light on the effects that probiotic microorganisms exert on pregnancy,
placing emphasis on the safety of these interventions.
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